T

The Acurio Health Group | Sydney Retina Clinic and Day Surgery

Research site

(Unclaimed)

Location

Level 13/187 Macquarie Street, Sydney, New South Wales, Australia

Site insights

Top conditions

Top treatments

Ranibizumab

Faricimab

APL-2

Zimura

Triamcinolone Acetonide

RG7774

IONIS-FB-LRx

Pegcetacoplan

JNJ-81201887

Abicipar Pegol

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 18 total trials

Locations recently updated

A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokin...

Enrolling

Neovascular Age-related Macular Degeneration (nAMD)

Device: Port Delivery System with Ranibizumab

Drug: Ranibizumab

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting

Geographic Atrophy

Drug: Triamcinolone

Other: Sham Procedure

A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (POYANG)

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in pa...

Enrolling

Choroidal Neovascularization Secondary to Pathologic Myopia

Procedure: Sham Procedure

Drug: Faricimab